Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
PharmAla Biotech Holdings, Inc. ( (TSE:MDMA) ) has shared an announcement.
PharmAla Biotech Holdings Inc. has successfully completed an international shipment of its LaNeo™ MDMA to the University of Washington for clinical research, highlighting the company’s role in supporting important human research studies in the United States. Despite the successful delivery, the company acknowledges the ongoing risk posed by US-Canada cross-border trade uncertainties and advocates for tariff exemptions on investigational drug products for US-funded research. Additionally, PharmAla has appointed Ali Taghva as Chief Commercial Officer to enhance its commercial operations.
More about PharmAla Biotech Holdings, Inc.
PharmAla Biotech Holdings Inc. is a biotechnology company specializing in the research, development, and manufacturing of MDXX class molecules, including MDMA. The company aims to alleviate the global shortage of clinical-grade MDMA for trials and commercial sales, and is the only provider of clinical-grade MDMA for patient treatments outside clinical trials. PharmAla is committed to regulatory excellence in the psychedelics industry.
YTD Price Performance: -29.63%
Average Trading Volume: 199,201
Technical Sentiment Consensus Rating: Sell
For an in-depth examination of MDMA stock, go to TipRanks’ Stock Analysis page.